Skip to main content
main-content

2020 | Mammakarzinom | OriginalPaper | Buchkapitel

31. Adjuvante Therapie des Mammakarzinoms

verfasst von: Marie Tzschaschel, Jens Huober

Erschienen in: Therapiehandbuch Gynäkologie und Geburtshilfe

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Damit für die am Mammakarzinom erkrankte Patientin die optimale Therapieentscheidung getroffen werden kann, ist es zunächst wichtig, das Mammakarzinom als systemische Erkrankung zu verstehen. Hierdurch werden auch die Therapieziele (Therapie des lokalen Tumors, Verhinderung von Rezidiv und Fernmetastasen) klar.
Literatur
Zurück zum Zitat Baselga J, Bradbury I, Eidtmann H (2012) First results of the NeoaLTTO trial (BIG 01-06/EGF 106903): lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoaLTTO): a randomized open label multicenter phase 3 trial. Lancet 379(9816):633–640 CrossRef Baselga J, Bradbury I, Eidtmann H (2012) First results of the NeoaLTTO trial (BIG 01-06/EGF 106903): lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoaLTTO): a randomized open label multicenter phase 3 trial. Lancet 379(9816):633–640 CrossRef
Zurück zum Zitat Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24(13):2019–2027 CrossRef Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24(13):2019–2027 CrossRef
Zurück zum Zitat Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE et al (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol 30(7):709–717 CrossRef Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE et al (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol 30(7):709–717 CrossRef
Zurück zum Zitat Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K et al (2016) Comparison of endopredict and epclin with oncotype dx recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108(11):djw149 CrossRef Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K et al (2016) Comparison of endopredict and epclin with oncotype dx recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108(11):djw149 CrossRef
Zurück zum Zitat Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia. J Clin Oncol 21(8):1431–1439 CrossRef Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia. J Clin Oncol 21(8):1431–1439 CrossRef
Zurück zum Zitat Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 15(9):997–1006 CrossRef Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 15(9):997–1006 CrossRef
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717 CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717 CrossRef
Zurück zum Zitat Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672–2685 CrossRef Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672–2685 CrossRef
Zurück zum Zitat Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32 CrossRef Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32 CrossRef
Zurück zum Zitat Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B et al (2013a) Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol 24(9):2206–2223 CrossRef Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B et al (2013a) Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol 24(9):2206–2223 CrossRef
Zurück zum Zitat Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, De Azambuja E, Procter M, Suter TM et al (2013b) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028 CrossRef Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, De Azambuja E, Procter M, Suter TM et al (2013b) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028 CrossRef
Zurück zum Zitat Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M et al (2016a) West German study group phase III planB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34(20):2341–2349 CrossRef Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M et al (2016a) West German study group phase III planB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34(20):2341–2349 CrossRef
Zurück zum Zitat Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH et al (2016b) Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 27(6):1035–1040 CrossRef Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH et al (2016b) Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 27(6):1035–1040 CrossRef
Zurück zum Zitat Gray R (EBCTCG) et al (2018) Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: a metaanalysis of 22192 women in 11 randomised trials. SABCS GS3-03 Gray R (EBCTCG) et al (2018) Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: a metaanalysis of 22192 women in 11 randomised trials. SABCS GS3-03
Zurück zum Zitat Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983 CrossRef Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983 CrossRef
Zurück zum Zitat Huober J, Von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133–140 CrossRef Huober J, Von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133–140 CrossRef
Zurück zum Zitat Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, Mclntyre KJ et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol 27(8):1177–1183 CrossRef Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, Mclntyre KJ et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol 27(8):1177–1183 CrossRef
Zurück zum Zitat Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 27(34):5685–5692 CrossRef Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 27(34):5685–5692 CrossRef
Zurück zum Zitat Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455–462 CrossRef Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455–462 CrossRef
Zurück zum Zitat Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25(19):2664–2670 CrossRef Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25(19):2664–2670 CrossRef
Zurück zum Zitat Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL et al (2003) HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21(3):453–457 CrossRef Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL et al (2003) HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21(3):453–457 CrossRef
Zurück zum Zitat Moebus V, Jackisch C, Lueck HJ, Du Bois A, Thomssen C, Kurbacher C et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874–2888 CrossRef Moebus V, Jackisch C, Lueck HJ, Du Bois A, Thomssen C, Kurbacher C et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874–2888 CrossRef
Zurück zum Zitat Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V et al (2015) Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 151(2):251–259 CrossRef Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V et al (2015) Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 151(2):251–259 CrossRef
Zurück zum Zitat Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8 · 1 years median follow-up. Lancet Oncol 12(12):1101–1108 CrossRef Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8 · 1 years median follow-up. Lancet Oncol 12(12):1101–1108 CrossRef
Zurück zum Zitat Romond EH, Perez E, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684 CrossRef Romond EH, Perez E, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684 CrossRef
Zurück zum Zitat Slamon D et al (2009) BCIRG 006 Phase 3 trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in the adjuvant treatment of HER2 – amplified e. Cancer Res Abstr 69(24 Suppl) Slamon D et al (2009) BCIRG 006 Phase 3 trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in the adjuvant treatment of HER2 – amplified e. Cancer Res Abstr 69(24 Suppl)
Zurück zum Zitat Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can. J Clin Oncol 23(31):7811–7819 CrossRef Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can. J Clin Oncol 23(31):7811–7819 CrossRef
Zurück zum Zitat Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C et al (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3):345–356 CrossRef Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C et al (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3):345–356 CrossRef
Zurück zum Zitat Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15(7):747–756 CrossRef Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15(7):747–756 CrossRef
Zurück zum Zitat von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al (2018) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617–628 von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al (2018) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617–628
Metadaten
Titel
Adjuvante Therapie des Mammakarzinoms
verfasst von
Marie Tzschaschel
Jens Huober
Copyright-Jahr
2020
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-59809-2_31

Passend zum Thema

ANZEIGE

ESMO Breast: Reduktion des Rezidivrisikos beim frühen Brustkrebs

Neben der endokrinen Therapie steht für Patientinnen und Patienten mit frühem HR+, HER2- Mammakarzinom und hohem Rezidivrisiko nun eine weitere Therapieoptionen zur Verfügung.

ANZEIGE

AGO-Leitlinie 2022: Update zu CDK4/6-Inhibitoren in der Adjuvanz

Die AGO hat ihre Leitlinien aktualisiert. Welchen Stellenwert haben CDK4/6-Inhibitoren in der adjuvanten endokrinen Therapie des HR+, HER2- eBCs sowie in der Erstlinientherapie des HR+, HER2- mBCs?

ANZEIGE

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom

Es erwarten Sie praxisrelevante Patientenfälle, kompakte Studiendarstellungen, informative Experteninterviews sowie weitere spannende Inhalte rund um das HR+, HER2- Mammakarzinom. 
 

Passend zum Thema

Galenus-Preis-Kandidat 2022 – Specialist Care

Trastuzumab-Deruxtecan – Chance bei fortgeschrittenem HER2-positivem Brustkrebs

Trastuzumab-Deruxtecan ist ein gegen das HER2-Protein gerichtetes Antikörper-Wirkstoff-Konjugat der neuesten Generation von Daiichi Sankyo, das zusammen mit AstraZeneca weiterentwickelt wird. In Monotherapie verzögert es die Progression von intensiv vorbehandeltem inoperablem oder metastasiertem HER2-positivem Brustkrebs.

Passend zum Thema

Galenus-Preis-Kandidat 2022 – Specialist Care

Sacituzumab Govitecan – Überlebensvorteil beim metastasierten triple-negativen Mammakarzinom

Sacituzumab Govitecan von Gilead Sciences ist das erste zur Behandlung des rezidivierten/refraktären triple-negativen Mammakarzinoms zugelassene Antikörper-Wirkstoff-Konjugat. Bei Betroffenen mit mindestens zwei Vortherapien verdoppelte das Medikament das Gesamtüberleben im Vergleich zu Chemotherapien.

Passend zum Thema

ANZEIGE

Krebsassoziierte Thrombose: NMH oder DOAK?

Vergleichsstudien gibt es mittlerweile einige, doch sind diese auf den klinischen Alltag übertragbar? Prof. Matzdorff, Schwedt, erläutert im Interview wichtige Entscheidungskriterien, die Ihnen mehr Sicherheit im Thrombosemanagement Ihrer Hochrisikopatienten geben.

Jetzt herunterladen: PDF: Publikation: Thromboseprophylaxe in der Onkologie und Schwangerschaft: 700,7 KB
ANZEIGE

Publikation: VTE-Inzidenz bei Krebs in den letzten 20 Jahren verdreifacht

Krebspatienten mit modernen Antikrebsmedikamenten sind vielleicht sogar stärker VTE-gefährdet als Patienten unter Chemotherapie. Auch Schwangere gehören zur VTE-Hochrisikogruppe. Über das Thrombosemanagement bei Risikopatienten diskutierten Experten auf dem DGA 2021. 

ANZEIGE

Management von Thromboembolien bei Krebspatienten

Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.